Zydus Lifesciences Ltd, a global innovation-led healthcare company, has announced the launch of VaxiFlu™, India’s first trivalent influenza vaccine (TIV). This milestone aligns with the latest World Health Organization (WHO) recommendations and marks a significant advancement in preventive healthcare.

Seasonal influenza continues to be a major global health challenge, causing 3–5 million severe cases and up to 650,000 respiratory deaths annually. Vulnerable groups such as infants, the elderly, and individuals with chronic conditions remain disproportionately affected. Given the rapid evolution of influenza viruses, annual vaccine updates are essential, with guidance provided by WHO’s Global Influenza Surveillance and Response System (GISRS).

The trivalent vaccine replaces the earlier quadrivalent version, as the influenza B/Yamagata strain has not been detected globally since 2020. Nearly 40 countries, including the US, have already transitioned to trivalent vaccines. Experts, including Dr. Parvaiz Koul (FRCP, FERS), have emphasized that continuing to vaccinate against a non-circulating strain holds no scientific merit.

Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, highlighted the company’s commitment to timely vaccine access, stating that vaccines are critical for reducing preventable diseases and complications in high-risk groups.

VaxiFlu™ is recommended for individuals aged six months and above and includes updated strains based on WHO’s surveillance, ensuring targeted protection for the current influenza season.